Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $125.93

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has received an average recommendation of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Fourteen investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $125.93.

Several research firms have recently issued reports on AXSM. Robert W. Baird lifted their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a research report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 target price for the company. Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $130.00 target price on shares of Axsome Therapeutics in a report on Tuesday, November 12th.

Axsome Therapeutics Trading Down 4.2 %

Shares of Axsome Therapeutics stock opened at $86.95 on Friday. The company has a 50-day moving average of $93.68 and a two-hundred day moving average of $88.16. The stock has a market cap of $4.21 billion, a PE ratio of -13.32 and a beta of 1.18. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period last year, the business posted ($1.32) EPS. On average, research analysts anticipate that Axsome Therapeutics will post -4.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds have recently modified their holdings of the stock. FMR LLC boosted its holdings in Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after purchasing an additional 23,564 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after purchasing an additional 8,125 shares during the period. Millennium Management LLC increased its position in Axsome Therapeutics by 1.4% during the 2nd quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock worth $59,555,000 after purchasing an additional 10,401 shares in the last quarter. Finally, Hood River Capital Management LLC raised its holdings in Axsome Therapeutics by 5.4% in the second quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock valued at $44,200,000 after buying an additional 28,316 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.